Stock Taper
IXHL
INCANNEX HEALTHCARE LIMITED
NASDAQ
$3.64
▼ DOWN 1.36% (-0.05)

KEY STATISTICS

Market Cap$43.55 M
52w High$20.64
52w Low$2.49
Dividend Yield
Frequency
P/E-5.31
Volume42.73K
Shares Out.11.96M

COMPANY

LEADERSHIP

Joel Bradley Latham
CHIEF EXECUTIVE
Joel Bradley Latham

COMPENSATION 2026

Salary$656,464
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$173,586
Total$1,127,739

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 2, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
12

UPCOMING EARNINGS

DateOct 5, 2026
DayMonday
Rev. Est.$200.00K
OCT
5
MON

SPLIT RECORD

DATETYPERATIO
2026-02-27Reverse1:30
2023-11-30Reverse1:4

PRICE

$3.64 ▼ DOWN 1.36% (−$0.05)
OVERLAYS
$3.60$3.65$3.70$3.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.64

About Incannex Healthcare Limited

https://www.incannex.com ↗

Incannex Healthcare Limited develops and sells pharmaceutical-grade cannabinoid products in Australia, including clinical-stage treatments for sleep apnea, brain injury, and inflammatory conditions, through partnerships with hospitals and research...

INDUSTRY

Biotechnology

A PRODUCT INCANNEX HEALTHCARE LIMITED IS KNOWN FOR

IHL-42X
IHL-42X

IHL-42X, Incannex's lead investigational oral drug combining dronabinol and acetazolamide for obstructive sleep apnea, is in Phase 2/3 trials with FDA Fast Track designation.

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

DIRECTOR
Valentine Troy
Purchase · 11.3M shares
2025-11-14
DIRECTOR
Clark Robert
Purchase · 1.7M shares
2025-11-14
DIRECTOR
Widdows Peter
Purchase · 1.7M shares
2025-11-14
OFFICER: CFO, TREASURER AND SECRETARY
Swan Joseph
Purchase · 869.6K shares
2025-11-14

SECTORS PEERS

PEERPRICE
AGEN$7.66COMPARE
IRD$3.69COMPARE
TTRX$9.84COMPARE
LUCD$0.99COMPARE
SEER$1.98COMPARE
CGTX$1.02COMPARE
ZYBT$1.73COMPARE
SCLX$5.43COMPARE